9 Questions
What is the most common form of lung cancer?
Non-small-cell lung cancer (NSCLC).
What drugs were tested for viability of cells expressing EGFR mutant?
Afatinib, erlotinib, and gefitinib.
What type of cancer did the patient present symptoms of?
Non-small cell lung cancer (NSCLC).
What is the significance of an epidermal growth factor (EGFR) mutation in NSCLC?
An EGFR mutation affects cell proliferation and sensitivity to available targeted therapies.
What was the less expensive treatment option according to the study?
EGFR mutation-guided erlotinib.
What is the significance of the EGFR mutation identified in the patient?
The EGFR mutation may make the patient more susceptible to EGFR inhibitors like erlotinib, gefitinib, and afatinib, which can be used as targeted therapies to treat the cancer.
What analysis was used to compare base-case costs and QALYs?
ICER analysis.
How do certain proteins influence tumour growth in relation to the EGFR mutation?
Through analysis, downregulation and upregulation of certain proteins (p21, cyclin D1 and IκBα) influences tumour growth in relation to the EGFR mutation.
Why is molecular profiling important in treating NSCLC?
Molecular profiling helps guide potential personalized treatment options for the patient based on the specific mutations present in the cancer cells.
Study Notes
- Viability of cells expressing EGFR mutant was tested with different drugs.
- EGFR mutation-guided use of afatinib, erlotinib, and gefitinib resulted in higher QALYs.
- Cisplatin-pemetrexed chemotherapy was used as empirical treatment without EGFR mutation testing.
- EGFR mutation-guided erlotinib was the less expensive treatment option.
- EGFR mutation-guided afatinib and gefitinib were more expensive than empirical chemotherapy.
- EGFR mutation-guided erlotinib was the preferred strategy from the viewpoint of the public healthcare provider in Hong Kong.
- ICER analysis was used to compare base-case costs and QALYs.
- EGFR mutation-guided erlotinib obtained greater QALYs with cost savings as compared with empirical chemotherapy.
- Probabilistic sensitivity analysis validated the base-case findings.
- IC50 value for the drug was 0.2901, indicating higher effectiveness.
Think you know about EGFR mutation-guided treatments for non-small cell lung cancer? Test your knowledge with this quiz! From different drug viabilities to cost-effective treatment options, this quiz covers various aspects of EGFR mutation-guided treatments. Keywords include EGFR mutation, afatinib, erlotinib, gefitinib, chemotherapy, QALYs, ICER analysis, and sensitivity analysis.
Make Your Own Quizzes and Flashcards
Convert your notes into interactive study material.
Get started for free
